All News

Patients in a phase 3 study reported better gastrointestinal tolerability with diroximel fumarate (Vumerity) compared with dimethyl fumarate (Tecfidera) in patients with relapsing forms of multiple sclerosis.

A study assessing melanoma cell variability indicates that identifying differences in cell states can be leveraged to improve patient outcomes.

Multiple health care organizations, including The American Hospital Association (AHA), the Institute for Safe Medication Practices (ISMP), and the American Society of Health-System Pharmacists (ASHP), have shown their full support for the MEDS Act.

An ongoing phase 2 study is evaluating SY-1425 plus azacitadine in newly-diagnosed unfit patients with acute myeloid leukemia.

Study suggests that men who use assisted reproduction techniques may benefit from early screening and long-term monitoring for prostate cancer.

Top news of the day from across the health care landscape

Top news of the day from across the health care landscape

Metabolic activity in the immune cells of patients with primary immunodeficiency was used as a biomarker due to cellular metabolism, which serves as a key regulator in immune cells.

What is causing this patient to lose her sense of smell?

Ron Lanton III, Esq., discusses the specialty pharmacist's role in educating patients about biosimilars and biologics.

Mylan Pharmaceuticals Inc. is operating a voluntary nationwide recall of one lot of Alprazolam Tablets, USP C-IV 0.5 mg to the consumer/user level. This recall stems from the potential presence of foreign substance, and to date, Mylan has not received any adverse events related to this batch.

Wild Poliovirus Type 3 (WPV3) has been eradicated worldwide, according to the Global Polio Eradication Initiative, a branch of the World Health Organization.

Officials with the FDA have expanded the use of Melinta Therapeutics’ delafloxacin (Baxdela) to include treatment of adult patients with community-acquired bacterial pneumonia caused by designated susceptible bacteria, but the drug’s availability will be delayed for this new indication.

National Institutes of Health experts discuss optimization of existing strategies for HIV treatment and prevention, as well as the development of new approaches.

Patients with non-Hodgkin lymphoma were more likely to discontinue treatment early when prescribed rituximab by physicians who had less experience with the drug.

Top news of the week from Specialty Pharmacy Times.

All 50 states accept the ExCPT exam from National Healthcareer Association (NHA), helping more pharmacy technicians earn a national credential.

Researchers have found that patients with high blood pressure (BP) who take all their antihypertensive medications at bedtime have better controlled blood pressure and a significantly lower risk of death or illness caused by heart or blood vessel problems, compared to patients who take their medications in the morning.1

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Top news of the day from across the health care landscape.

Ron Lanton III, Esq., discusses challenges in launching biosimilars after they've been approved.

Psoriasis may increase the risk of cancer incidence and cancer-related mortality in affected individuals.

Effective December 31, 2019, Amgen’s 60% annual list price cut for evolocumab (Repatha) will be fully implemented.

Genentech has announced the results of a Phase III study which showed that atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) increased overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC).

Officials from the FDA have cleared an investigational new drug (IND) application for BW-1010 (BlueWillow Biologics), according to the company. The drug would be the company’s next-generation anthrax vaccine candidate.

Officials with the FDA have approved Allergan’s supplemental Biologics License Application (sBLA) for onabotulinumtoxinA (BOTOX®) to expand its indication to include treatment of pediatric patients, ages 2 to 17 years, with lower limb spasticity, excluding spasticity caused by cerebral palsy.

The influenza A virus remains contagious in wet mucus from infected patients, even after being exposed to an ethanol-based disinfectant.

McKesson’s Health Mart has announced a partnership with Amazon Hub Counter pickup points, offering customers more convenient delivery options.